<DOC>
	<DOC>NCT00000349</DOC>
	<brief_summary>The purpose of this study is to evaluate clinical safety issues pertaining to flupenthixol, to cocaine, and to their interaction, and to determine how pretreatment with flupenthixol modifies the subjective as well as physiological effects of cocaine. Taken together, these relatively D-1 selective agents can help determine the extent to which DA-1 binding affects the reinforcing effects of stimulants.</brief_summary>
	<brief_title>Infusion Laboratory: Protocol 5 (Flupenthixol) - 14</brief_title>
	<detailed_description />
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Flupenthixol</mesh_term>
	<mesh_term>Flupenthixol decanoate</mesh_term>
	<criteria>M/F, ages 2150. Meet DSMIV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent. Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>cocaine dependence</keyword>
</DOC>